AU2006304418B2 - Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis - Google Patents

Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis Download PDF

Info

Publication number
AU2006304418B2
AU2006304418B2 AU2006304418A AU2006304418A AU2006304418B2 AU 2006304418 B2 AU2006304418 B2 AU 2006304418B2 AU 2006304418 A AU2006304418 A AU 2006304418A AU 2006304418 A AU2006304418 A AU 2006304418A AU 2006304418 B2 AU2006304418 B2 AU 2006304418B2
Authority
AU
Australia
Prior art keywords
plgf
tumor
antibody
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006304418A
Other languages
English (en)
Other versions
AU2006304418A1 (en
Inventor
Chien Hsing Chang
David M. Goldenberg
Alice P. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Center for Molecular Medicine and Immunology
Original Assignee
Immunomedics Inc
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, Center for Molecular Medicine and Immunology filed Critical Immunomedics Inc
Publication of AU2006304418A1 publication Critical patent/AU2006304418A1/en
Application granted granted Critical
Publication of AU2006304418B2 publication Critical patent/AU2006304418B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
AU2006304418A 2005-10-19 2006-10-16 Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis Ceased AU2006304418B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19
PCT/US2006/040431 WO2007047609A2 (en) 2005-10-19 2006-10-16 INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS

Publications (2)

Publication Number Publication Date
AU2006304418A1 AU2006304418A1 (en) 2007-04-26
AU2006304418B2 true AU2006304418B2 (en) 2013-03-28

Family

ID=37963183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006304418A Ceased AU2006304418B2 (en) 2005-10-19 2006-10-16 Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis

Country Status (8)

Country Link
US (3) US7642239B2 (enExample)
EP (1) EP1937724A4 (enExample)
JP (1) JP5498018B2 (enExample)
KR (1) KR101287280B1 (enExample)
CN (2) CN101534865A (enExample)
AU (1) AU2006304418B2 (enExample)
CA (1) CA2625992C (enExample)
WO (1) WO2007047609A2 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
WO2008073828A2 (en) * 2006-12-08 2008-06-19 Northwestern University Compositions and methods for magnetic resonance imaging contrast agents
US20080299077A1 (en) * 2007-06-01 2008-12-04 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2008151021A1 (en) * 2007-06-01 2008-12-11 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
EP2278993A4 (en) * 2008-05-16 2012-09-12 Corthera Inc METHOD FOR PROMOTING HEALING
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
CA2736929C (en) * 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
US8940331B2 (en) * 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
SG10201604988YA (en) * 2008-12-23 2016-07-28 Genentech Inc Methods and compositions for diagnostic use in cancer patients
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
AU2010215196B2 (en) 2009-02-21 2015-04-16 Covidien Lp Crosslinked fibers and method of making same by extrusion
WO2010095045A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8968818B2 (en) 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
CA2753173C (en) 2009-02-21 2017-05-30 Sofradim Production Medical devices with an activated coating
EP2398584A2 (en) 2009-02-21 2011-12-28 Sofradim Production Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
EP2398523B1 (en) 2009-02-21 2018-04-04 Covidien LP Medical devices having activated surfaces
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8663689B2 (en) * 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
CA2753165A1 (en) 2009-02-21 2010-08-26 Sofradim Production Compounds and medical devices activated with solvophobic linkers
EP2398943B1 (en) 2009-02-21 2013-04-17 Sofradim Production Crosslinked fibers and method of making same using uv radiation
EP2398583B1 (en) 2009-02-21 2020-12-23 Sofradim Production Apparatus and method of reacting polymers passing through metal ion matrix to produce injectable medical devices
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
JP5798125B2 (ja) * 2009-12-15 2015-10-21 チェ，ムヒョン 単量体に結合特異性がある結合体の反復鎖と多数単量体の複合体内での架橋結合の生成増加を通じた二量体及び多量体の生産方法
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
EP2550031B1 (en) 2010-03-25 2015-08-19 Sofradim Production Medical devices incorporating functional adhesives
US9272074B2 (en) * 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
CA2804263A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US8981075B2 (en) * 2010-07-02 2015-03-17 National University Corporation Tokyo University Of Agriculture And Technology PSA binding aptamer and method for diagnosis of prostate cancer
AU2011284449B2 (en) 2010-07-27 2015-07-23 Sofradim Production Polymeric fibers having tissue reactive members
CN102028955A (zh) * 2010-08-09 2011-04-27 华中科技大学同济医学院附属同济医院 一种用于肿瘤基因干预的新型靶向复合物
CN102680619A (zh) * 2011-03-09 2012-09-19 北京康华源医药信息咨询有限公司 一种胶体金属定量检测技术及其用途
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
CN102505180A (zh) * 2011-09-16 2012-06-20 彭可扬 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜
WO2013079713A1 (en) * 2011-12-01 2013-06-06 Thrombogenics Nv Improving trabeculectomy outcome
CN103087196B (zh) * 2012-06-26 2016-12-21 青岛大学附属医院 胞壁酰二肽-抗cd20免疫偶联物制备方法及应用
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN104837508A (zh) * 2012-12-13 2015-08-12 免疫医疗公司 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
US10052351B2 (en) 2014-01-17 2018-08-21 Mimedx Group, Inc. Method for inducing angiogenesis
US9895419B2 (en) 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
TWI625123B (zh) 2014-03-31 2018-06-01 分離胎盤中雌激素之方法
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN105669871A (zh) * 2016-04-19 2016-06-15 中国药科大学 一种胸腺肽α1的融合蛋白
EP4245775A3 (en) * 2016-04-29 2023-11-15 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
CN109689692B (zh) 2016-06-22 2021-11-12 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
WO2018137609A1 (zh) 2017-01-24 2018-08-02 本康生物制药（深圳）有限公司 抗体偶联物、相关的药物组合物及应用
CN106596911B (zh) * 2016-12-16 2019-07-19 石河子大学 一种证明缝隙连接在高血压炎症反应中的作用的试验方法
EP3655049A2 (en) * 2017-11-22 2020-05-27 Firmenich SA Method of identifying laundry malodor, moldy malodor and/or sweat malodor modulating compounds
CN110326584B (zh) * 2019-07-04 2020-06-19 西安交通大学 一种p物质诱导的过敏性哮喘动物模型的构建方法和筛选药物的方法
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
CN114404367B (zh) * 2021-12-29 2023-02-21 中山大学附属第一医院 一种通过对病变细胞靶向分布的纳米载体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180286A1 (en) * 2000-05-12 2003-09-25 Peter Carmeliet Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
US20040053837A1 (en) * 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7727971B2 (en) * 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US6930089B2 (en) * 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
PT2295070E (pt) * 2000-04-12 2015-12-07 Life Sciences Res Partners Vzw Utilização de vegf e homólogos para tratar distúrbios do neurónio
WO2002046213A2 (en) * 2000-11-07 2002-06-13 Gpc Biotech Inc. Methods and reagents for isolating angiogenic modulators
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
CA2491053A1 (en) * 2002-06-28 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of antibodies against flt-1 for the treatment of osteoporosis
RU2356909C2 (ru) * 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
HRP20120477T1 (hr) * 2005-03-24 2012-07-31 ThromboGenics@N@V Nova anti plgf protutijela

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180286A1 (en) * 2000-05-12 2003-09-25 Peter Carmeliet Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMAD SHAKIL et al Circulation Research, Vol 95, No. 9, page 884-891, 29 October 2004 *
HORNING, C. et al Laboratory Investigation, Vol 80, No. 4, page 443-454, 1 April 2000 *

Also Published As

Publication number Publication date
AU2006304418A1 (en) 2007-04-26
US20100216662A1 (en) 2010-08-26
US7642239B2 (en) 2010-01-05
US7932212B2 (en) 2011-04-26
CN101534849A (zh) 2009-09-16
JP5498018B2 (ja) 2014-05-21
JP2009514813A (ja) 2009-04-09
WO2007047609A2 (en) 2007-04-26
KR101287280B1 (ko) 2013-07-23
US20110189268A1 (en) 2011-08-04
EP1937724A4 (en) 2009-11-04
KR20080055932A (ko) 2008-06-19
CA2625992C (en) 2014-05-27
CA2625992A1 (en) 2007-04-26
CN101534865A (zh) 2009-09-16
US20070087001A1 (en) 2007-04-19
WO2007047609A3 (en) 2009-03-19
EP1937724A2 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
AU2006304418B2 (en) Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis
CA2607056C (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
US10118961B2 (en) Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
ES2938628T3 (es) Agentes de unión a VEGF/DLL4 y usos de los mismos
US9169470B2 (en) Methods and compositions for generating bioactive assemblies of increased complexity and uses
JP2024161402A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
JP2020531045A (ja) 抗ｃｄ１６６抗体およびその使用
US20080182258A1 (en) Q3 sparc deletion mutant and uses thereof
JP2006519163A (ja) 癌転移および癌転移に伴なう骨量減少を防止および処置するための方法
JP2002543093A (ja) Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
CA2939941A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
EP4130046A1 (en) Platform for constructing multispecific antibody
CN101820910A (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
US20050003466A1 (en) Aminopeptidase a (APA) targeting peptides for the treatment of cancer
CN117659203B (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
EP3145545B1 (en) Bak binding proteins
EP4567045A1 (en) Anti-ddr2 nano-antibody and use thereof
WO2025098542A2 (zh) 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用
US20240199735A1 (en) Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
CN115558029A (zh) 靶向pd-1的双特异性抗体、及其制备和应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO INCLUDE CO-INVENTOR TAYLOR, ALICE P

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ INHIBITI ON OF PLACENTA GROWTH FACTOR (PIGF) MEDIATED METASTASIS AND/OR ANGIOGENESIS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired